Evaluating the Diagnostic Activity of TDP-43 PET Tracer in FTD & ALS for Earlier Diagnosis & Treatment in Humans
Time: 11:00 am
day: Conference Day One Track B
Details:
- Discovery and characterization of the first in class TDP-43 PET tracer sensitivity
- Delving into the preclinical characterization of ACI-19626 to correlate TDP-43 pathology with disease progression
- Clinical trial design
- Exploring early clinical data to show temporal TDP-43 aggregate change with longitudinal disease progression in humans, for improved disease staging in a heterogenous ALS population
- Understanding the potential to combine this data with fluid TDP-43 cryptic exon biomarkers, to better predict patient benefit for TDP-43 targeted therapeutics
